Benitec Biopharma Inc. reported that prior financial statements for December 31, 2024, and March 31, 2025, should not be relied upon due to errors in recording share-based compensation, with restatements expected in their upcoming 10-K filing. These adjustments stemmed from a data migration issue that led to underreported expenses, affecting reported capital and losses.